AdaptHealth stock just absorbed a brutal judgment from the market, plunging 38% to US$6.71 after its Q2 release. Investors focused on a sharp reset to full year adjusted EBITDA guidance and a fresh loss from continuing operations, rather than the solid top line of US$740.3 million and double digit growth in core Sleep and Respiratory. The short term readout is simple: profitability pressure is front and center.

The bigger story now runs through the next few years. AdaptHealth is leaning hard into a higher risk capitated model and carrying heavier leverage. The key question for investors is whether this profit squeeze is a passing execution hit or a structural warning.

Is AdaptHealth now a deep value opportunity after this 38% sell off, or a stock the market expects to stay under pressure for longer? Compare the current price against our detailed valuation analysis for AdaptHealth.

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs. Q2 2025): US$740.3 million vs. US$800.4 million (a decrease of 7.5%).
• Net Income from Continuing Operations (Q2 2026 vs. Q2 2025): loss of US$156.7 million vs. profit of US$13.4 million (indicating weaker profitability).
• Basic EPS (Q2 2026 vs. Q2 2025): loss of US$1.07 per share vs. earnings of US$0.10 per share (a shift from profit to loss).
• Adjusted EBITDA Margin from Continuing Operations (Q2 2026 vs. Q2 2025): 17.8% vs. a prior-year level that was modestly higher (reflecting margin pressure tied to contract and cost headwinds).

Prefer clear visuals instead of scrolling through dense earnings tables and guidance changes? View AdaptHealth's complete financial picture, with an emphasis on valuation, in a simple, interactive format in our company report for AdaptHealth.

Evaluating AdaptHealth’s Growth Story Against Q2 Reality

Bulls argue AdaptHealth can use capitated contracts, technology, and focused M&A to build a high quality, recurring revenue engine with better margins over time. Q2 shows mixed progress. Sleep Health and Respiratory Health together delivered strong double digit revenue growth and capitated revenue reached US$103.3m, now about 14% of continuing revenue. This supports the idea that the capitation model is scaling and gaining relevance.

The bullish view also leans on technology and digital workflow to support this shift. Management pointed to the myAPP platform with 512,000 users and early traction from an AI mask fitting tool as concrete adoption milestones. At the same time, adjusted EBITDA margin of 17.8% and negative free cash flow of US$20.9m, driven by heavy capex for the West Coast contract, indicate that the recurring revenue and tech build out are not yet translating into cleaner profitability.

Compare that internal progress with how the street is recalibrating expectations. See the consensus price target analysis for AdaptHealth to check where analyst targets sit after this 38% drop.

AdaptHealth Bears See Profitability Risks Playing Out

The bearish view on AdaptHealth centers on the idea that the pivot to capitated revenue, heavy capex and reimbursement pressure could lock the company into weaker margins and thinner free cash flow than the story promised. Q2 results give that concern real traction. Capitated revenue reached US$103.3m and is growing in relevance, yet adjusted EBITDA margin sat at 17.8% and free cash flow swung to a loss of US$20.9m, with US$166.2m of capex tied largely to the West Coast contract.

Bears have also warned that execution missteps and payer dynamics might force a reset to earnings power. The US$55m guidance downgrade linked to the West Coast contract, the US$30m expected hit from a manufacturer price spike and the US$144.2m goodwill impairment are clear milestones missed. Combined with a 38% share price drop after the print, the profitability and execution worries look validated rather than disproved.

After a 38% share price fall and a goodwill impairment, are these setbacks isolated or early signs of deeper structural fragility? Review the risk analysis for AdaptHealth which shows 1 important warning sign.

Stay Ahead Of Your Next Move

If the 38% drop in AdaptHealth has your attention, register for free with Simply Wall St and add it to your Watchlist to track price against fair value and watch how the thesis evolves. After you decide to take a position, use the Portfolio Command Center to keep your holdings organised and only surface the updates that actually matter. For long term context and fresh angles, tap into the Community to see how other investors are thinking about AdaptHealth and similar stocks. By spotting potential catalysts and risks early, you give yourself a better chance to stay ahead of the market rather than reacting to it.

Seeking Alternatives Beyond AdaptHealth Stock

Fresh ideas tend to move first when momentum builds, while slower money gets caught chasing breakouts after the best entry points are gone. Scan these under the radar lists and act now.

• Spot resilient cash generators before they start flying by running your own shortlist using the curated list of solid balance sheet and fundamentals stocks (49 results).
• Ride structural trends instead of short term noise by scanning the focused 36 power grid technology and infrastructure stocks while these infrastructure plays are still under the radar for now.
• Target compounders with real earnings momentum by combing through the hand picked 68 profitable AI stocks that aren't just burning cash before the crowd starts chasing the same charts.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.